● Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

Condition: Pulmonary Disease, Chronic Obstructive · Sponsor: GlaxoSmithKline

PhasePhase 3

Planned participants1196

Who can joinAll sexes, 40 Years to 75 Years

Healthy volunteersNo

About this study

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

This description comes directly from the study's public registry record.

Talk to the study team

US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com

Always discuss trial participation with your own doctor first.

Locations (121)

GSK Investigational Site	Newport Beach, California, United States	Recruiting
GSK Investigational Site	Lakewood, Colorado, United States	Recruiting
GSK Investigational Site	Brandon, Florida, United States	Recruiting
GSK Investigational Site	Crystal River, Florida, United States	Recruiting
GSK Investigational Site	Doral, Florida, United States	Recruiting
GSK Investigational Site	Greenacres City, Florida, United States	Recruiting
GSK Investigational Site	Hialeah, Florida, United States	Recruiting
GSK Investigational Site	Hollywood, Florida, United States	Recruiting
GSK Investigational Site	Miami, Florida, United States	Recruiting
GSK Investigational Site	Miami, Florida, United States	Recruiting
GSK Investigational Site	Miami, Florida, United States	Recruiting
GSK Investigational Site	Miami Lakes, Florida, United States	Recruiting

+ 109 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07177339